In 2022, the research group obtained 3 research projects, continued its participation in European projects, has published 4 scientific articles, submitted 4 patents, and presented communications at various national and international conferences. In addition, members of the group participated in national and international committees and commissions both in the field of advanced therapy and scientific policy in general, in addition to coordinating the VHIR eCORE AVANT. The group is also participating in 2 crowdfunding campaigns, one coordinated by the Fundación la Lucha de Abril focused on SPG52, and another coordinated by “El gen Rebelde” focused on GNB1 encephalopathy, which altogether have raised more than €100,000 during 2022. We would also like to highlight the Vector Production Unit (UPV) which in 2022 has generated more than 250 viral batches for academic groups and private companies from 7 different countries, with a turnover of approx €450,000.

Group Leader
Miguel Chillon Rodriguez

Principal Investigator (PI)
Assumpció Bosch, Beatriz Almolda, Juan Francisco Espinosa

Researchers
Angel Edo, Susana Miravet, Angela Sanchez

PhD Students
Laura Rodriguez, Rebeca Blanch, Joan Roig, Jon Esandi, Alejandro Brao, Sergi Verdes, Andrea Onieva, Ruben Guerrero

Lab Technicians
Javier del Rey, Jorge Lunar, Laia Rubio, Marc Cabrera, Miriam Calles, Elsa Ibarrola, Israel Alcazar, Marina Tarres

4

PUBLICATIONS

75.0%

%Q1

27

IMPACT FACTOR

6.84

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Ángel Edo, Laura Calvo-Barreiro, Herena Eixarch, Assumpció Bosch, Miguel Chillón, and Carmen Espejo
Therapeutic effect of IL21 blockage by gene therapy in Experimental Autoimmune Encephalomyelitis
Neurotherapeutics, 2022; 19: 1617-1633
DOI: doi: 10.1007/s13311-022-01279-8
IF: 6.088

J. Roig-Soriano, C. Griñán-Ferré, J.F. Espinosa-Parrilla, C. R. Abraham, A. Bosch, M. Pallàs, M. Chillon
AAV-mediated expression of αKlotho isoforms rescues relevant aging hallmarks in senescent SAMP8 mice
Aging Cell, 2022, Apr;21(4):e13581
DOI: doi: 10.1111/acel.13581
IF: 11.005

Marc Leal-Julià, Jorge J. Vilches, Andrea Onieva, Sergi Verdés, Ángela Sánchez, Miguel Chillón, Xavier Navarro, Assumpció Bosch
Proteomic quantitative study of dorsal root ganglia and sciatic nerve in type 2 diabetic mice
Molecular Metabolism, 2022, Jan;55:101408
DOI: doi: 10.1016/j.molmet.2021.101408
IF: 8.568

Júlia Companys-Alemany, Joan Roig-Soriano, Andreea L. Turcu, Miguel Chillón, Santiago Vázquez, Mercè Pallàs, Christian Griñán-Ferré,
Optimized N-methyl-D-aspartate receptor antagonist exhibits hippocampal proneurogenic effects in aged senescence-accelerated mouse prone 8 mice
NeuroReport, 2022, Oct 5;33(14):623-628.
DOI: doi: 10.1097/WNR.0000000000001825
IF: 1.703

Plataforma personalitzada per l’anàlisi de fàrmacs antiepilèptics
Principal Investigator: Miguel Chillon
Agency: AGAUR. Modalitat A. Llavor Indústria del Coneixement.
Funding: 20,000€
Period: 2022-2023

REDES DE TERAPIAS AVANZADAS (TERAV). RD21/0017/0008
Principal Investigator: Miguel Chillon /Assumpcio Bosch / Jordi Barquinero
Agency: ISCIII. REDES DE INVESTIGACIÓN COOPERATIVA ORIENTADAS A RESULTADOS EN SALUD (RICORS)
Funding: 163,225.70 €
Period: 2021-2024

Desarrollo de nuevas terapias genéticas basadas en inteinas. RTC2019006879-1
Principal Investigator: Miguel Chillon
Agency: Ministerio Ciencia Innovación. Retos Colaboración
Funding: 215,713.13 €
Period: 2020-2023

Personalized gene therapy for MECP2 using CRISPR/Cas9 technology together with AAV administration in 3D cell cultures and Kl mice
Principal Investigator: Miguel Chillon
Agency: European Joint Programme-Rare Diseases and ISC-III EJP RD JTC 2020. AC20/00051
Funding: 169,097.50€
Period: 2021-2023

Molecular and functional characterization of new recombinant chimeric chronokines. Implications for cognitive decline associated with aging
Principal Investigator: Miguel Chillon
Agency: Ministerio Ciencia Innovación. Proyectos I+D+i Retos Sociedad. PID2019-104034RB-I00
Funding: 121,000€
Period: 2020-2023

Secreted splicing variant of Klotho for treating muscle disorders
Priority Number: EP22383173.6
Priority Date: 02/12/2022
Applicants: UAB, ICREA, VHIR; UPF

Secreted splicing variant of Klotho for extending lifespan
Priority Number: EP22383171.0
Priority Date: 02/12/2022
Applicants: UAB, ICREA, VHIR

Nucleic acid constructs and vectors for podocyte specific expression
Priority Number: EP22382421.0
Priority Date: 02/05/2022
Applicants: UAB, ICREA, VHIR, Ninevah

Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
Priority Number: US-63/330.684
Priority Date: 13/04/22
Applicants: UAB, ICREA, VHIR, CIBERNED

eCOREs